A Novel Cyclic Biased Agonist of the Apelin Receptor, MM07, Is Disease Modifying in the Rat Monocrotaline Model of Pulmonary Arterial Hypertension

British Journal of Pharmacology - United States
doi 10.1111/bph.14603
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Effects of Inorganic Nitrate in a Rat Model of Monocrotaline‐induced Pulmonary Arterial Hypertension

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

Frontiers in Pharmacology
Pharmacology
2018English

GPR143, a L-Dopa Receptor, Is Involved in Monocrotaline-Induced Pulmonary Hypertension in Rats

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Calorie Restriction Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats

Journal of Cardiovascular Pharmacology
Cardiovascular MedicinePharmacologyCardiology
2015English

Riociguat Is a Novel Medication for the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Medical Council
2016English

New Treatment Options for Pulmonary Arterial Hypertension — The First Selective IP-receptor Agonist Selexipag

Cardiovascular Therapy and Prevention (Russian Federation)
Cardiovascular MedicineCardiology
2019English

Interventions and Mechanisms of N‑acetylcysteine on Monocrotaline‑induced Pulmonary Arterial Hypertension

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome

Scientific Reports
Multidisciplinary
2018English

Rosuvastatin, Sildenafil and Their Combination in Monocrotaline-Induced Pulmonary Hypertension in Rat

Acta Pharmaceutica
MedicinePharmacologyPharmaceutical Science
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy